Macrophage migration inhibitory factor, Toll-like receptor 4, and CD14 polymorphisms with altered expression levels in patients with ulcerative colitis

Gunisetty, Sivaram; Tiwari, Santosh Kumar; Bardia, Avinash; Anjum, Farha; Vishnupriya, S.; Habeeb, Aejaz; Khan, Aleem Ahmed

doi:10.1016/j.humimm.2011.12.006

Cited by 24 publications

(16 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, MIF involvement has been demonstrated in immunological and inflammatory diseases [15, 16] such as septic shock [17], cancer [18], and chronic diseases including bowel disease [19], rheumatoid arthritis [20–22], colitis [23], obesity [24–26], and diabetes [25, 27, 28]. More recently, MIF was proposed as a diagnostic biomarker for autoimmune diseases such as arthritis, ulcerative colitis, and diabetes [23, 29, 30]. …”

Section: Introductionmentioning

confidence: 99%

The Role of MIF in Type 1 and Type 2 Diabetes Mellitus

Sánchez-Zamora

Rodrı́guez-Sosa

2014

Journal of Diabetes Research

View full text Add to dashboard Cite

Autoimmunity and chronic low-grade inflammation are hallmarks of diabetes mellitus type one (T1DM) and type two (T2DM), respectively. Both processes are orchestrated by inflammatory cytokines, including the macrophage migration inhibitory factor (MIF). To date, MIF has been implicated in both types of diabetes; therefore, understanding the role of MIF could affect our understanding of the autoimmune or inflammatory responses that influence diabetic pathology. This review highlights our current knowledge about the involvement of MIF in both types of diabetes in the clinical environment and in experimental disease models.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of MIF in Type 1 and Type 2 Diabetes Mellitus

Sánchez-Zamora

Rodrı́guez-Sosa

2014

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…The underlying pathogenesis of CD remains unclear, but may result from interactions between environmental, immunological and bacterial factors (3). Various countries and nationalities have demonstrated different incidence rates of CD, which cannot be explained by living habits or other risk factors, suggesting that genetic polymorphisms may be crucial in the development of CD (4,5). Recently, studies have indicated that polymorphism of the immunity-related GTPase M ( IRGM ) gene is associated with an increased CD risk (6,7).…”

Section: Introductionmentioning

confidence: 99%

IRGM rs13361189 polymorphism may contribute to susceptibility to Crohn’s disease: A meta-analysis

Lin

et al. 2014

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of the present meta-analysis was to evaluate the correlation between a common polymorphism, rs13361189 C>T in the immunity-related GTPase M (IRGM) gene, and susceptibility to Crohn’s disease (CD). The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library and CBM databases were investigated from database inception through to October 1, 2013 without the application of any language restrictions. The meta-analysis was performed using STATA 12.0 software and the relative risk (RR) with a 95% confidence interval (CI) was calculated. Seven case-control studies were included with a total of 3,093 CD patients and 3,227 healthy control subjects. The results of the meta-analysis revealed that the IRGM rs13361189 polymorphism correlates with an increased risk of CD (T allele versus C allele: RR=1.25 with 95% CI, 1.04–1.50; P=0.016 and CT + TT versus CC: RR=1.21 with 95% CI, 1.03–1.42; P=0.018). A subgroup analysis conducted using a genotyping method indicated that the IRGM rs13361189 polymorphism was correlated with an increased risk of CD in the TaqMan® (T allele versus C allele: RR=1.32 with 95% CI, 1.01–1.73; P=0.042) and the polymerase chain reaction-restriction fragment length polymorphism subgroups (T allele versus C allele: RR=1.80 with 95% CI, 1.32–2.45; P<0.001 and CT + TT versus CC: RR=1.61 with 95% CI, 1.19–2.18; P=0.018). However, no correlation was observed in the direct sequencing subgroup (P>0.05). Further subgroup analysis by sample size demonstrated significant correlations between the IRGM rs13361189 polymorphism and an increased risk of CD in the large sample-size subgroup (T allele versus C allele: RR=1.46 with 95% CI, 1.26–1.68; P<0.001 and CT + TT versus CC: RR=1.40 with 95% CI, 1.21–1.62; P<0.001). However, no correlation was identified between the IRGM rs13361189 polymorphism and CD risk in the small sample-size subgroup (P>0.05). The present meta-analysis indicated that the IRGM rs13361189 polymorphism may contribute to susceptibility to CD. Thus, IRGM rs13361189 polymorphism may be a potential biomarker for the early diagnosis of CD.

show abstract

“…Among IBD cases, 1072 were diagnosed with CD and 1210 with UC. One study was excluded because the distribution of genotypes in the control group was inconsistent with HWE [18]. Four of the seven included publications described case-control studies involved Caucasians [12–14,17], while the remaining three publications involving Asians [11,15,16].…”

Section: Resultsmentioning

confidence: 99%

The -173 G/C Polymorphism of the MIF Gene and Inflammatory Bowel Disease Risk: A Meta-Analysis

Shen

Guo

Yang

et al. 2013

IJMS

View full text Add to dashboard Cite

The -173 G/C polymorphism in the macrophage migration inhibitory factor (MIF) gene has been implicated in susceptibility to inflammatory bowel disease (IBD), but the results are inconclusive. The present meta-analysis aimed to investigate the overall association between the -173 G/C polymorphism and IBD risk. We searched in Pubmed, and Embase for studies evaluating the association between the -173G/C gene polymorphism and IBD risk. Data were extracted and statistical analysis was performed using Revman 5.1 and STATA 12.0 software. A total of seven publications involving 4729 subjects (2282 IBD cases and 2447 controls) were included in this meta-analysis. Combined analysis revealed a clear association between this polymorphism and IBD susceptibility (OR = 1.48, 95% CI: 1.10–2.00, p = 0.009 for CC vs. CG + GG). Subgroup analysis by ethnicity showed that the IBD risk associated with the -173G/C gene polymorphism was significantly elevated among Asians (OR = 1.79, 95% CI: 1.08–2.96, p = 0.02), but not among Caucasians. Subgroup analysis by disease suggested that the -173G/C gene polymorphism is a risk factor for ulcerative colitis (OR = 1.62, 95% CI: 1.10–2.37, p = 0.01), but that it was not associated with Crohn’s disease. This meta-analysis suggests that the -173 G/C polymorphism in the macrophage MIF gene contributes to IBD susceptibility, specifically in Asian populations. Further studies are needed to validate these findings.

show abstract

Macrophage migration inhibitory factor, Toll-like receptor 4, and CD14 polymorphisms with altered expression levels in patients with ulcerative colitis

Cited by 24 publications

References 33 publications

The Role of MIF in Type 1 and Type 2 Diabetes Mellitus

The Role of MIF in Type 1 and Type 2 Diabetes Mellitus

IRGM rs13361189 polymorphism may contribute to susceptibility to Crohn’s disease: A meta-analysis

The -173 G/C Polymorphism of the MIF Gene and Inflammatory Bowel Disease Risk: A Meta-Analysis

Contact Info

Product

Resources

About